Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it

Page 6 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.

• Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)WithdrawnNCT03504566Phase 4
• Vildagliptin on Gastric AccommodationCompletedNCT03500900Not applicable
• A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin TherapyCompletedNCT03499704Phase 4
• Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial InfarctionCompletedNCT03486080Phase 2
• Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESStatus unknownNCT03433248Phase 4
• Omarigliptin & Trelagliptin in Twelve Healthy Egyptian VolunteersCompletedNCT03362398Not applicable
• A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin TherapyStatus unknownNCT03320031Phase 4
• An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican VolunteersCompletedNCT03310749Phase 1
• Metformin Versus Vildagliptin for Diabetic Hypertensive PatientsCompletedNCT03253562Phase 4
• Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)CompletedNCT03202563Phase 4
• Effects of DPP4 Inhibitor Versus SGLT2 InhibitorCompletedNCT03178591Phase 4
• A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.CompletedNCT03169959Phase 1
• Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus SulfonylureaCompletedNCT03125694Phase 3
• Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary SyndromeCompletedNCT03122041Phase 4
• Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.CompletedNCT03088670Phase 3
• Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine DepartmentStatus unknownNCT03051243Phase 3
• Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes MellitusWithdrawnNCT03042325Phase 4
• Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two PatientsCompletedNCT03011177Phase 4
• Teneligliptin-Glimepiride DDI StudyCompletedNCT03009513Phase 1
• Effect of Linagliptin + Metformin vs Metformin Alone in Patients With PrediabetesCompletedNCT03004612Phase 4
• Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)CompletedNCT02974504Phase 4
• Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 DiabetesCompletedNCT02949193Phase 3
• A Clinical Trial to Investigate the Efficacy and Safety of EvogliptinCompletedNCT02946541Phase 3
• Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight LossCompletedNCT02941445Phase 4
• Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT02920801Phase 4
• Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 DiabetesStatus unknownNCT02900417Not applicable
• HbA1c Variability in Type II DiabetesActive, not recruitingNCT02879409Not applicable
• Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)CompletedNCT02857946Phase 1
• A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes MellitusCompletedNCT02853630Phase 4
• Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular GeometryCompletedNCT02851745Phase 3
• Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant PeriodCompletedNCT02849899Phase 3
• Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)CompletedNCT02831361Phase 3
• CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)CompletedNCT02827890Phase 1
• The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy VolunteersStatus unknownNCT02826044Phase 1
• The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes PatientsStatus unknownNCT02822534Phase 1
• the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy VolunteersStatus unknownNCT02821871Phase 1
• The DDI Study of SP2086 and SimvastatinStatus unknownNCT02817243Phase 1
• The DDI Study of SP2086 and ValsartanStatus unknownNCT02817217Phase 1
• Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)CompletedNCT02816970Phase 1
• The Drug -Drug Interaction of SP2086 and GlyburideCompletedNCT02815787Phase 1
• SP2086 Pharmacokinetic Study in Renal Insufficiency PatientsCompletedNCT02815774Phase 1
• The Metabolite Identification and Material Balance Study of SP2086CompletedNCT02815748Phase 1
• The Drug-drug Interaction of SP2086 and SimvastatinCompletedNCT02815722Phase 1
• The Drug-drug Interaction of SP2086 and ValsartanCompletedNCT02815657Phase 1
• The Drug-drug Interaction of SP2086 and MetforminCompletedNCT02813863Phase 1
• Monotherapy With Rapamycin in Long-standing Type 1 DiabetesCompletedNCT02803892Phase 2
• The Effect of DPP4 Inhibitor on Vasclular HealingStatus unknownNCT02802644Phase 4
• The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin MonotherapyCompletedNCT02798172Not applicable
• The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsCompletedNCT02792400Not applicable
• The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End ProductsWithdrawnNCT02768220Phase 4
• An Extension Study of PEAK TrialTerminatedNCT02763007Phase 4
• Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic DysfunctionCompletedNCT02754219Phase 1
• Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mgCompletedNCT02753803Phase 1
• Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 DiabetesCompletedNCT02752113Phase 3
• Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) SecretionCompletedNCT02749032Phase 1
• Drug Transporter Interaction Study PHENTRA_2015_KPUKCompletedNCT02743260Phase 4
• Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic UlcersStatus unknownNCT02742233Phase 4
• Incretin Axis in Type 1 Diabetes MellitusStatus unknownNCT02725502Not applicable
• Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)CompletedNCT02689362Phase 2
• Accelerated Wound Healing in Diabetic Ulcers by SitagliptinWithdrawnNCT02675335Phase 3
• BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered AloneStatus unknownNCT02670070Phase 1
• BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered AloneStatus unknownNCT02670018Phase 1
• Effect of Sitagliptin on Progression of Coronary Intermediate LesionCompletedNCT02655757Phase 4
• TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.CompletedNCT02653209Phase 4
• The Use of DPP-4 Inhibitors in Short Bowel SyndromeTerminatedNCT02653131Phase 4
• A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver ResectionCompletedNCT02650427Phase 1
• Initial Combination of Gemigliptin and Metformin on Microbiota ChangeCompletedNCT02609815Not applicable
• Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2DCompletedNCT02607410Phase 4
• Effect of Evogliptin on Bone Metabolism in HumanStatus unknownNCT02587975Phase 4
• Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 DiabetesStatus unknownNCT02583438Phase 4
• Sitagliptin Effects on Arterial Vasculature and Inflammation in ObesityCompletedNCT02576288Phase 2
• Tenelia Triple Combination StudyCompletedNCT02567994Phase 3
• Treatment of Hypoglycemia Following Gastric Bypass SurgeryCompletedNCT02527993Phase 4
• Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)CompletedNCT02512523Phase 4
• Phase 1 Bioavailability Study of SYR-322METCompletedNCT02508168Phase 1
• The Drug-drug Interaction of SHR3824 and SP2086Status unknownNCT02500485Phase 1
• Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM PatientsStatus unknownNCT02500329Phase 4
• Saxagliptin and Cardiac Structure and FunctionCompletedNCT02481479Phase 4
• Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic PatientsStatus unknownNCT02462369Phase 4
• Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus StudyStatus unknownNCT02449330Phase 4
• Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes MellitusWithdrawnNCT02444364Early Phase 1
• Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DMStatus unknownNCT02443922Not applicable
• Linagliptin and Mesenchymal Stem Cells: A Pilot StudyCompletedNCT02442817Phase 4
• Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune DiabetesCompletedNCT02407899Phase 4
• Sitagliptin and Endothelial DysfunctionStatus unknownNCT02406950Phase 3
• Effects of Linagliptin in Addition to Empagliflozin on Islet Cell PhysiologyCompletedNCT02401880Phase 4
• Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic ClampStatus unknownNCT02386943Phase 4
• Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and AlbuminuriaCompletedNCT02376075Phase 3
• Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)CompletedNCT02347501Phase 2
• Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedNCT02338921Phase 4
• Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass SurgeryCompletedNCT02336659Not applicable
• Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes TrialCompletedNCT02330406Phase 4
• Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 DiabetesCompletedNCT02315495Phase 3
• The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 DiabetesStatus unknownNCT02307695Phase 4
• Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell FunctionCompletedNCT02304081Phase 4
• Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DMStatus unknownNCT02301806Phase 4
• Sitagliptin and Brown Adipose TissueCompletedNCT02294084Phase 4
• Effects of Saxagliptin on Adipose Tissue Inflammation in HumansCompletedNCT02285985Phase 4
• Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With MetforminCompletedNCT02280486Phase 4
• Effect of Linagliptin on TRL MetabolismStatus unknownNCT02280174Phase 4

← Dipeptidyl-Peptidase IV Inhibitors overview